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Abstract
Background: Resistance of cholangiocarcinoma to chemotherapy is a major problem in cancer
treatment. The mechanism of resistance is believed to involve phosphoinositide-3- kinase (PI3K)/
Akt activation. Although the platinum-containing compound oxaliplatin has been extensively used
in the treatment of several solid tumors, recent data regarding its use to treat cholangiocarcinoma
are ambiguous. Oxaliplatin resistance in this disease could potentially involve PI3K pathways. We,
therefore, examined the effects of PI3K pathways in cholangiocarcinoma cells in modulating
oxaliplatin resistance.
Results: After exposing the cholangiocarcinoma cell lines RMCCA1 and KKU100 to oxaliplatin,
the levels of Akt and mTOR phosphorylation increased, as shown by western blot analysis. The
WST-1 cell proliferation assay showed increased inhibition of cell growth under high
concentrations of oxaliplatin. The combination of oxaliplatin with LY294002, an inhibitor of PI3K,
resulted in a remarkable arrest of cell proliferation. Deactivation of mTOR by RAD001 was also
synergistic with oxaliplatin, although to a lesser extent. The combination of oxaliplatin and a PI3K
inhibitor also resulted in a significant induction of apoptosis, as demonstrated by the TUNEL assay.
Conclusion: Activation of PI3K might protect cholangiocarcinoma cells from oxaliplatininduced
cytotoxicity. Although the inhibition of PI3K and the inhibition of mTOR both enhance oxaliplatin-
induced cytotoxicity, PI3K inhibition has a greater effect. Targeting the PI3K pathway may be a
useful approach to improve the chemotherapeutic sensitivity of cholangiocarcinoma.
Background
Cholangiocarcinoma is a cancer characterized by early
vascular invasion and metastasis. Patients with cholangi-
ocarcinoma are often diagnosed at advanced stage. Three-
year survival rates of 35% to 50% can be achieved only in
a subset of patients, who have negative histological mar-
gins at the time of surgery [1]. Palliative therapeutic
approaches consisting of percutaneous and endoscopic
biliary drainage have usually been used for these patients,
since there is no effective chemotherapeutic treatment for
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this type of cancer [2]. A novel agent, oxaliplatin, has been
extensively used as chemotherapeutic agent in treating
solid tumors [3,4]. Oxaliplatin is a diaminocyclohexane
platinum compound that acts like cisplatin to induce
DNA adducts formation. Although early studies suggested
that oxaliplatin might be used as an active agent against
cholangiocarcinoma [5,6], more recent data indicated
that cholangiocarcinoma cells were resistant to oxaliplatin
[7]. Therefore, elucidating the mechanism of resistance to
oxaliplatin in cholangiocarcinoma cells is crucial to
improve the treatment of patients with advanced cholan-
giocarcinoma.
Activation of the phosphoinositide-3-kinase (PI3K)/Akt
signaling pathway is frequently found in cholangiocarci-
noma cells [8]. It has been suggested to be a key step lead-
ing to the resistance of cancer cells to chemotherapy,
especially when using DNA-damaging agents such as cis-
platin and oxaliplatin [9,10]. Furthermore, previous stud-
ies have demonstrated that PI3K/Akt activation regulates
sensitivity of cells to G1 arrest induced by mTOR inhibi-
tors [11]. Taken together, these data indicate that chemo-
therapeutic agents might function better in killing cancer
cells if the PI3K pathway is blocked. In this study, we
hypothesize that inhibition of PI3K or its downstream tar-
get, mTOR, may be increase oxaliplatin efficacy in treating
cholangiocarcinoma. The effect of PI3K and mTOR inhi-
bition on oxaliplatin sensitivity of cholangiocarcinoma
cells is examined.
Methods
Cell culture and Materials
Ham's F12 medium and fetal bovine serum (FBS) were
purchased from Gibco (Gibco, Grand Island, NY, USA).
Polyclonal antibodies to Akt (phosphorylated at Ser473
and total), mTOR, PP70S6K and P38 MAPK (phosphor-
ylated at Thr180/Tyr182 and total) were purchased from
Cell Signaling (Cell Signaling Technology, Beverly, MA,
USA). Oxaliplatin was purchased from Sanofi Aventis
(Sanofi Aventis, Bridgewater, NJ, USA). Cell culture plastic
plates were obtained from Nunc (Thermo Fisher, Roches-
ter, NY, USA). LY294002 (PI3K inhibitor) was purchased
from Calbiochem (EMD Chemicals, Gibbstown, NJ,
USA). RAD001 (everolimus), an oral derivative of
rapamycin, was generously provided by Novartis Pharma
AG (Novartis International AG, Basel, Switzerland). Stock
solutions (10 mmol/L) were dissolved in DMSO (Sigma-
Aldrich, St. Louis, MO, USA), stored at -80°C, and diluted
in fresh medium immediately before use.
The human intrahepatic cholangiocarcinoma cell lines
RMCCA1 [12] and KKU100 (kindly provided by Dr. Ban-
chob Sripa, Department of Pathology, Faculty of Medi-
cine, Khon Kaen University) were grown in Ham's F12
medium supplemented with 10% FBS at 37°C in a 5%
CO2 humidified atmosphere. For experiments, cells were
grown in Ham's F12 medium supplemented with 1% FBS.
Cell proliferation assay
For proliferation assay, cells were seeded in 96-well cul-
ture plastic plates at a density of 10,000 cells per well.
Vehicle (PBS) or oxaliplatin in various concentrations (0–
200 μM) were added to each well. For the Akt or mTOR
inhibition studies, cells were treated with Vehicle
(DMSO), LY294002 (PI3K inhibitor) or RAD001 (mTOR
inhibitor), respectively, for 1 hour before the addition of
oxaliplatin. Cells were then incubated for 48 hours before
applying the WST-1 cell proliferation assay reagent (Roche
Diagnostics, Laval, Quebec, Canada), according to the rec-
ommendation of the manufacturer. The amount of cell
proliferation was assessed by determining the A450 nm of
the cell culture media after addition of WST-1 for 2 hours.
Results were reported as percentage of the inhibition of
cell proliferation, where the optical density measured
from vehicle-treated cells was considered to be 100% of
proliferation. Percentage of inhibition of cell proliferation
was calculated as follows: (1-Aexp group/Acontrol) × 100.
Cell apoptosis assay
The number of apoptotic cells was determined with the
Apo-BrdU TUNEL assay kit (Invitrogen, Carlsbad, CA,
USA), following manufacturer's instructions. Briefly, cells
were washed with cold PBS and then fixed with 1% para-
formaldehyde and ice-cold 70% ethanol for 30 minutes.
Fixed cells were labeled with BrdUTP using terminal deox-
ynucleotide transferase (TdT) at 37°C for 60 minutes and
stained with Alexa Fluor 488-labeled anti-BrdU antibody
for 30 minutes at room temperature. To score for apopto-
sis, cells were counterstained with DAPI, and at least 200
cells were counted under fluorescent microscope at 400×
magnification. The percentage of apoptotic cells per
experimental condition was then determined.
Western blotting analyses
Approximately 500,000 cells were seeded in a six-well cul-
ture plate, followed by treatment with vehicle (PBS), or
oxaliplatin for 12 hours. Cells were collected, washed with
PBS and lysed in lysis buffer. Western blot analyses were
performed as previously described [8]. The blots were first
probed with antibodies against phospho-Akt, phospho-
mTOR, phospho-P70S6K or cleaved caspase-3 and then
reprobed with antibodies against total Akt, mTOR,
P70S6K or caspase-3. Bound antibodies were detected
using chemiluminescence.
Statistical analysis
The experiments were all performed in triplicate, and each
result is reported as the mean with SD. Data between three
or more groups were compared using the one-way analy-
sis of variance, followed by Dunnett's post hoc test. A p-Cancer Cell International 2009, 9:3 http://www.cancerci.com/content/9/1/3
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value of less than 0.05 was considered statistically signifi-
cant.
Results
Oxaliplatin slightly inhibits cholangiocarcinoma cell 
proliferation
Cholangiocarcinoma cells were treated with 0–200 μM
oxaliplatin for 48 hours, and then a cell proliferation
assay was performed using WST-1. The percentage of cell
proliferation inhibition was set at 0% when the cells were
treated with vehicle (PBS). Both RMCCA1 and KKU100
displayed a slight dose-sensitivity to oxaliplatin. For
RMCCA1, the inhibition of cell proliferation was 14.0% ±
6.54 and 28.7% ± 7.33 in cells treated with 100 and 200
μM of oxaliplatin, respectively. For KKU100, the inhibi-
tion of cell proliferation was 8.1% ± 3.31 and 15.6% ±
3.30 in cells treated with 100 and 200 μM of oxaliplatin,
respectively (Figs. 1A and 1B).
Phosphorylation of Akt and mTOR was induced by 
oxaliplatin in cholangiocarcinoma cells
Previous studies demonstrated that activation of PI3K
pathway induced chemoresistance in cancer cells. To
assess PI3K activation in cholangiocarcinoma cells after
treatment with oxaliplatin, the levels of phosphorylated
Akt and mTOR, two downstream signal transduction mol-
ecules in the PI3K pathway, were examined. Cholangi-
ocarcinoma cells were treated with 0–200 μM of
oxaliplatin for 12 hours or treated with 100 μM of oxali-
platin for 0–48 hours. Cells were then subjected to west-
Effect of oxaliplatin on cholangiocarcinoma cells Figure 1
Effect of oxaliplatin on cholangiocarcinoma cells. (A) RMCCA1 and (B) KKU100 cells were treated with oxaliplatin at 
various concentrations (0, 10, 50, 100 and 200 μM) for 48 hours. Effect on cell proliferation was measured by WST-1 and ana-
lyzed by spectrophotometric analysis (Absorbance = 450 nm). Results are reported as percentage inhibition of cell prolifera-
tion, where the optical density value from vehicle-treated cells was set as 100% of proliferation. Results are represented by the 
mean ± SE of three independent experiments. Phosphorylation of Akt and mTOR in (C) RMCCA1 and (D) KKU100 cells fol-
lowing 0–200 μM oxaliplatin treatment for 12 h and phosphorylation of Akt and mTOR in (E) RMCCA1 and (F) KKU100 cells 
following 100 μM oxaliplatin treatments for 0–48 h were determined by western blotting. Total Akt and mTOR were used as 
loading control. Representatives of the three independent experiments are shown.Cancer Cell International 2009, 9:3 http://www.cancerci.com/content/9/1/3
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ern blot analysis. The levels of Akt and mTOR
phosphorylation increased as the concentration of oxali-
platin increased (Figs. 1C and 1D). In addition, the
increase in the levels of phosphorylated Akt and mTOR is
observed as early as 12 hours and as late as 48 hours after
oxaliplatin treatment in both cell lines (Figs. 1E and 1F).
This result is in agreement with that from a previous
study, indicating that the mechanism of cell protection to
chemotherapeutic agent is through the activation of the
PI3K pathway [9,12].
Inhibition of PI3K and mTOR increases the cytotoxicity of 
oxaliplatin in cholangiocarcinoma cell lines
To evaluate the effect of the PI3K pathway on oxaliplatin
resistance, cholangiocarcinoma cells were treated with
specific inhibitors of PI3K (LY294002) and mTOR
(RAD001), with or without oxaliplatin. Western blot anal-
ysis was used to determine the levels of phosphorylation
of Akt and P70S6K, the downstream targets of PI3K and
mTOR, respectively. Cell growth was determined by the
cell proliferation assay. When treated with LY294002, the
cells clearly exhibit lower levels of Akt and P70S6K phos-
phorylation compared to what is seen under control con-
ditions. RAD001 also significantly reduced the
phosphorylation of P70S6K, but it increased the phos-
phorylation of Akt (Figs. 2A and 2B).
Oxaliplatin-induced resistance of cells was shown to be
modulated by inhibitors of either Akt or mTOR. Cholan-
giocarcinoma cells were pretreated with either 10 μM
LY294002 or 0.5 μM RAD001 for 1 hour, followed by
incubation with 0–200 μM oxaliplatin. Pretreatment with
LY294002 resulted in a two-fold increase in the percent-
age of inhibition of cell proliferation at both 100 and 200
μM of oxaliplatin when compared to the control
(RMCCA1; from 14.1% ± 3.76 to 35.1% ± 5.14 at 100 μM
oxaliplatin; p = 0.002 and from 28.6% ± 7.25 to 57.4% ±
7.19 at 200 μM oxaliplatin; p = 0.004 and KKU100; from
8.1% ± 2.33 to 20.7% ± 1.98 at 100 μM oxaliplatin; p =
0.09 and from 15.5% ± 4.02 to 30.7% ± 5.10 at 200 μM
oxaliplatin; p = 0.01, (Figs. 2C and 2D). Pretreatment with
RAD001 resulted in increased inhibition of cell prolifera-
tion only at high concentrations of oxaliplatin (RMCCA1;
from 14.1% ± 3.76 to 20.5% ± 4.37 at 100 μM oxaliplatin;
p = 0.2 and from 28.7% ± 7.25 to 45.3% ± 6.20 at 200 μM
oxaliplatin; p = 0.04 and KKU100; from 8.1% ± 2.33 to
12.6% ± 2.54 at 100 μM oxaliplatin; p = 0.20 and from
15.5% ± 4.02 to 22.0% ± 2.58 at 200 μM oxaliplatin; p =
0.006). The significant increase of oxaliplatin-induced
cytotoxicity in cholangiocarcinoma cells upon pretreat-
ment with specific kinase inhibitors indicates that resist-
ance of cholangiocarcinoma cells to chemotherapeutic
agents can be modulated.
LY294002 increases oxaliplatin-induced cell apoptosis
In order to determine the mechanism by which LY294002
and RAD001 increase oxaliplatin-induced cytotoxicity,
TUNEL apoptosis assays were performed. 10 μM
LY294002, 0.5 μM RAD001 or control vehicle (DMSO)
were added to RMCCA1 cholangiocarcinoma cells, fol-
lowed by treatment of the cells with 0–200 μM oxaliplatin
for 48 hours. Exposure to either LY294002 or RAD001
alone did not significantly alter the number of RMCCA1
apoptotic cells when compared to the control. However,
the combination of LY294002 with 100–200 μM oxalipl-
atin significantly increased the number of apoptotic cells
(from 21.8% ± 7.33 to 45.6% ± 6.13 at 100 μM oxalipla-
tin; p = 0.008 and from 34.5% ± 6.72 to 62.4% ± 6.68 at
200 μM oxaliplatin; p = 0.004). In contrast, the combina-
tion of RAD001 with 100–200 μM oxaliplatin did not sig-
nificantly increase the number of apoptotic cells (Figs. 3A
and 3B).
To verify that apoptosis was the direct cause of cell death,
the presence of cleaved caspase-3, a central marker of
apoptosis, was determined by western blot analysis. As
shown in Fig. 3C, the level of cleaved caspase-3 was very
low in cholangiocarcinoma cells treated with 10 μM of
LY294002, 0.5 μM of RAD001 or oxaliplatin alone. On
the other hand, the level of cleaved caspase-3 was
increased in cholangiocarcinoma cells treated with
LY294002 in combination with 100 or 200 μM of oxalipl-
atin.
Discussion
Cholangiocarcinoma is a rapidly lethal disease and gener-
ally considered to be incurable. One of the main reasons
for its low survival rate is that cholangiocarcinoma exhib-
its extensive local invasion and frequent regional lymph
node metastasis. Most patients are not candidates for cur-
ative surgical resection [13]. Until recently, there has been
no effective chemotherapeutic drug for this disease.
Oxaliplatin has been used for the treatment of a number
of solid tumors including lung, gastric, and colorectal can-
cer [[3,6], and [14]]. Recently, a prospective multicenter
phase II study focused on capecitabine and oxaliplatin
(CAPOX) combination therapy in advanced cholangi-
ocarcinoma [3,7]. Unfortunately, the results suggested
that this regimen produced poor results for intrahepatic
cholangiocarcinoma [7]. An alternative strategy is then
needed to evaluate the efficacy of oxaliplatin as chemo-
therapeutic agent. We used two cholangiocarcinoma cell
lines, RMCCA1 and KKU100, derived from cholangiocar-
cinoma patients to study the effect of oxaliplatin in vitro.
These cell lines exhibited resistance to oxaliplatin, even at
high concentrations (100–200 μM). In addition, we dem-Cancer Cell International 2009, 9:3 http://www.cancerci.com/content/9/1/3
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onstrated that oxaliplatin-treated cholangiocarcinoma
cells exhibit high levels of Akt and mTOR phosphoryla-
tion as a result of PI3K activation. Thus, we hypothesized
that activation of the PI3K pathway in cholangiocarci-
noma cells may, in turn, protect the cells from oxaliplat-
ininduced cytotoxicity. Our results indeed showed that
inhibition of Akt by LY294002 significantly increased
oxaliplatin efficacy in inhibiting cell proliferation. This
finding suggests that Akt phosphorylation might be attrib-
uted to oxaliplatin resistance in cholangiocarcinoma cells.
This result is also consistent with recent evidence showing
that the mechanism of drug resistance in cancer cells was
primarily through the induction of PI3K/Akt pathways
[15].
Previous studies demonstrated that exposure of cancer
cells to oxaliplatin induced protein misfolding. These mis-
folded proteins are prone to oxidative stress as a result of
better accessibility of reactive oxygen species (ROS) to the
protein structure [16]. As a consequence, recruitment of
Inhibition of Akt and mTOR increases the oxaliplatin-induced cytotoxicity in cholangiocarcinoma cell lines Figure 2
Inhibition of Akt and mTOR increases the oxaliplatin-induced cytotoxicity in cholangiocarcinoma cell lines. The 
effects of Akt (LY294002), and mTOR (RAD001) inhibitors on the phosphorylation of Akt and P70S6K in (A) RMCCA1 and 
(B) KKU100 cells were determined by western blotting. Total Akt and P70S6K were used as loading controls. Cells were 
treated with 10 μM LY294002, 0.5 μM RAD001 or control vehicle (DMSO) for 24 hours. Representatives from 3 independent 
experiments are shown. The effects of LY294002 and RAD001 in (C) RMCCA1 and (D) KKU100 cells following treatment 
with or without oxaliplatin are shown. Cells were treated with 10 μM LY294002, 0.5 μM RAD001 or control vehicle (DMSO), 
followed by the addition of 0–200 μM oxaliplatin for 48 hours. Cell proliferation was measured by WST-1 and analyzed by 
spectrophotometric analysis (Absorbance = 450 nm). Results are reported as a percentage inhibition of cell proliferation, 
where the optical density value from vehicle-treated cells were set as 100% of proliferation and represent the mean ± SE of 
three independent experiments. (*, p < 0.05 versus the same concentration of oxaliplatin)Cancer Cell International 2009, 9:3 http://www.cancerci.com/content/9/1/3
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Bax to the mitochondria, release of cytochrome c to the
cytosol, activation of caspase-3 and apoptotic cell death
take place in cancer cells treated with oxaliplatin.
Recently, Kim et al. reported that the activation of Akt
could inhibit oxaliplatininduced apoptosis through
maintaining XIAP protein levels [10]. In this study, we
demonstrate that inhibition of Akt by LY294002 increases
the percentage of apoptotic cells after oxaliplatin treat-
ment. In addition, activation of caspase-3 was clearly
observed in cholangiocarcinoma cells treated with both
LY294002 and oxaliplatin. These data indicate that activa-
tion of Akt in cholangiocarcinoma cells may be the key
mechanism in inhibiting oxaliplatin-induced apoptosis.
PI3K and Akt regulate the processes of cellular glucose
metabolism. Inactivation of PI3K and Akt may have dele-
terious effects on normal cell metabolism [17]. Therefore,
only inhibitors of those downstream molecules of PI3K
and Akt that are not involved in glucose metabolism
should be considered for clinical treatment. The mamma-
lian target of rapamycin is mTOR, a 289 kDa serine/thre-
onine kinase. mTOR is a downstream effector of the PI3K/
Akt signaling pathway involved in the regulation of many
transduction processes of cell growth as well as cell cycle
progression, membrane trafficking, protein degradation,
and protein kinase C signaling and transcription [18].
Recently, a derivative of rapamycin, RAD001
(everolimus), has been developed. RAD001 has been
shown to inhibit mTOR activity, thereby halting the pro-
liferation of cancer cells, both in vitro and in vivo. Phase II
clinical trials with RAD001 are currently being performed
for many types of cancers [18,19]. Based on the results of
our study, the 0.5 μM RAD001 alone did not inhibit the
proliferation of cholangiocarcinoma cells. This is consist-
ent with a previous study, which demonstrated that
RAD001 has only cytostatic effects in cancer cells. To
induce cytotoxicity of RAD0001 in cancer cells, other
LY294002 modulated oxaliplatin-induced cell apoptosis Figure 3
LY294002 modulated oxaliplatin-induced cell apoptosis. (A) Cells were added with 10 μM LY294002, 0.5 μM RAD001 
or control vehicle and then treated with 0–200 μM oxaliplatin. TUNEL assay was done as described in the Methods section. 
The percentage of apoptotic cells in each group of treatments was demonstrated (values shown as mean ± SD, *; p < 0.05 ver-
sus the same concentration of oxaliplatin). (B) Apoptotic cells (green spots) were detected with an ApopTag Staining kit and 
counterstained with DAPI (blue). RMCCA1 cells were treated with Vehicle (a) and 100 μM oxaliplatin (b). Cells were treated 
with RAD001 plus 100 μM oxaliplatin (c) and with LY294002 plus 100 μM oxaliplatin (d) (Arrow head indicates the apoptotic 
cells). (C) Western blots analysis of cleaved caspase-3 and caspase-3 in each group of treatments. The blots were representa-
tive of three independent experiments.Cancer Cell International 2009, 9:3 http://www.cancerci.com/content/9/1/3
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chemotherapeutic drugs should be combined with
RAD0001 [18,20]. For example, pretreating ovarian can-
cer cells with RAD001 can increase their sensitivity to cis-
platin [21]. In this study, we found that RMCCA1 and
KKU100 displayed high levels of Akt and mTOR phos-
phorylation after treatment with oxaliplatin. Pretreatment
of cholangiocarcinoma cells with 0.5 μM RAD001 signifi-
cantly increased the sensitivity of oxaliplatin when used at
200 μM. However, pretreatment with 0.5 μM RAD001 did
not significantly increase the efficacy of oxaliplatin when
used at 100 μM. In addition, the number of apoptotic cells
and the activation of caspase-3 did not significantly
increase when the cells were exposed to both RAD001 and
oxaliplatin. This might be explained by the fact that inhi-
bition of P70S6K by RAD001 induces IGF-IR/IRS-1/PI3K
signaling, eventually increasing the level of Akt phospho-
rylation [22]. This feedback mechanism might be respon-
sible for the decrease in sensitivity to oxaliplatin, leading
to a reduction in the inhibition of cell proliferation. These
results are consistent with the recent report that inhibition
of mTOR resulted in Akt activation in several human can-
cer cell lines [22].
In summary, this study presents the possible mechanism
in oxaliplatin resistance in cholangiocarcinoma cells. As
proof-of-concept, we are able to show that activation of
the Akt signaling pathway has a potent effect on oxalipla-
tin resistance. The model presented here may serve as a
practical tool for identifying the molecular mechanism of
chemotherapeutic drug-resistance in cholangiocarcinoma
cells.
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